Related Experiment Video

Updated: Apr 24, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.4K

RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell

Sumanta K Pal1, Miaoling He2, Tommy Tong3

  • 1Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.

Molecular Cancer Research : MCR
|September 4, 2014
PubMed
Abstract

Insights

Sarcomatoid metastatic renal cell carcinoma (mRCC) shows increased cell proliferation and aurora kinase A (AURKA) expression. Targeting AURKA and mTOR may offer new therapeutic strategies for this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Sarcomatoid metastatic renal cell carcinoma (mRCC) presents a poor prognosis with limited biological understanding.
  • Characterizing the distinct cellular components of sarcomatoid mRCC is crucial for identifying therapeutic targets.

Purpose of the Study:

  • To investigate the molecular differences between sarcomatoid and clear cell components in mRCC.
  • To identify key signaling pathways and molecular targets in sarcomatoid mRCC.

Main Methods:

  • RNA sequencing (RNA-seq) was performed on adjacent benign, clear cell, and sarcomatoid RCC tissue components.
  • Quantitative PCR (qPCR) and Immunohistochemistry (IHC) were used to validate gene and protein expression.
  • Functional studies involved stable expression of AURKA in an RCC cell line.

Main Results:

  • Sarcomatoid components exhibited enriched M phase and cell-cycle pathways, indicating higher proliferation compared to clear cell components.
  • Increased expression of Aurora Kinase A (AURKA) was observed in sarcomatoid tissue and correlated with enhanced mTOR pathway activity.
  • Overexpression of AURKA in an RCC cell line activated the mTOR pathway.

Conclusions:

  • Sarcomatoid RCC demonstrates a proliferative phenotype driven by increased AURKA expression.
  • AURKA-dependent activation of mTOR signaling is a key feature of sarcomatoid RCC.
  • Targeting AURKA and/or mTOR pathways presents a promising therapeutic strategy for sarcomatoid mRCC.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K